MAJIC-PV Trial: Ruxolitinib vs Best Available Therapy in Hydroxyurea-Resistant/Intolerant Polycythemia Vera


With their final discussion the panel examines the survival outcomes and risk of thromboembolic/hemorrhagic events from the MAJIC-PV trial, which compared ruxolitinib to best available therapy in polycythemia vera patients resistant or intolerant to hydroxyurea.

Recent Videos
Related Content